Blueprint Medicines (NASDAQ:BPMC) just reported results for the first quarter of 2024.
- Blueprint Medicines reported earnings per share of -$1.32. This was above the analyst estimate for EPS of -$1.66.
- The company reported revenue of $96.12 million.
- This was 19.50% better than the analyst estimate for revenue of $80.43 million.